Galectin Therapeutics Secures $10M Credit Line Following FDA Feedback on NAVIGATE NASH Cirrhosis Trial

Introduction

GALECTIN THERAPEUTICS INC (NASDAQ: GALT) is a clinical-stage biotechnology company headquartered in Norcross, Georgia. As of December 19, 2025, its stock price closed at $3.98, reflecting a decline of 35.39% on trading volume of 1,743,278 shares. The company utilizes carbohydrate-based technology to develop therapies targeting galectin proteins associated with fibrosis, cirrhosis, and cancer.

Corporate Structure

Founded in 2000, Galectin Therapeutics employs between 11 and 50 staff members across research, development, and administrative functions. The company’s leadership team encompasses expertise in carbohydrate chemistry, clinical trial management, and regulatory affairs. Galectin maintains academic collaborations to advance its pipeline and is open to additional partnership opportunities.

Biotechnology by Louis Reed

Recent Developments and News

On December 19, 2025, Galectin Therapeutics reported receiving a written response from the U.S. Food and Drug Administration (FDA) regarding its NAVIGATE clinical study in NASH cirrhosis. Concurrently, the company secured a $10 million line of credit from investor Richard E. Uihlein, which is expected to support operations through March 2027.
On November 14, 2025, Galectin reported financial results for the quarter ended September 30, 2025, stating it ended the period with $11.53 million in cash while continuing to invest in its lead candidates. On November 10, 2025, the company presented data from the NAVIGATE trial at the American Association for the Study of Liver Diseases (AASLD) annual meeting.

Financial and Strategic Analysis

Galectin’s share price has decreased from a 52-week high of $7.13 to its current level, reflecting challenges common among clinical-stage biotechnology companies. As of the third quarter of 2025, the company reported a trailing net loss of $37.44 million and negative free cash flow of $24.14 million.
The recent $10 million credit facility enhances liquidity in conjunction with the existing cash balance of $11.53 million. Management has indicated that these funds will support planned expenditures for the NAVIGATE study and other early-stage programs through the first quarter of 2027. Continued progress in clinical endpoints, regulatory milestones, and external collaborations will be vital for future financing or partnership opportunities.

Market Position and Industry Context

Galectin operates within the pharmaceutical manufacturing sector, focusing on liver fibrosis, NASH cirrhosis, and tumor vaccine enhancement. Currently, there is no approved therapy for NASH cirrhosis, making Galectin’s NAVIGATE study—testing belapectin in a Phase 2b/3 trial—one of the few adaptive trials in this area. The broader market for NASH treatments includes various candidates at multiple stages of development, but few specifically target cirrhosis without established varices. Success in this specific niche may differentiate Galectin from its competitors and address an increasing demand for liver transplants.

tl;dr

On December 19, 2025, Galectin Therapeutics disclosed an FDA written response concerning its NAVIGATE NASH cirrhosis trial and secured a $10 million credit line from Richard E. Uihlein, extending its financial runway to March 2027. The company reported $11.53 million in cash and a net loss of $37.44 million for Q3 2025. Future events include additional NAVIGATE data releases and potential partnership announcements.